Current opinion in anaesthesiology
Suzetrigine, a selective NaV1.8 inhibitor in acute and chronic pain: mechanistic insights, clinical outcomes, and future perspectives.
Steven L Chen, Matthew A Liu, Matthew W Swisher
Published: 202510.1097/ACO.0000000000001599
Abstract
PURPOSE OF REVIEW: The opioid epidemic and limitations of current nonopioid analgesics have created a need for safer, effective pain therapies. Suzetrigine, a first-in-class selective NaV1.8 inhibitor, was approved by the Food and Drug Administration…
Preview only. Read the full abstract at the source